Gates Package — page 255

Members of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Partnership Carlos Garner, Ph.D. Vice President, Global Regulatory Affairs Eli Lilly and Company David Goff, M.D., Ph.D. Director, Division of Cardiovascular Sciences National Heart, Lung, and Blood Institute, NIH Penny Heaton, Ph.D. Chief Executive Officer Bill & Melinda Gates Medical Research Institute Michael Kurilla, M.D., Ph.D. (Co-Chair) Director, Division of Clinical Innovation National Center for Advancing Translational Sciences, NIH George Mensah, M.D. Director, Center for Translation Research & Implementation Science National Heart, Lung, and Blood Institute, NIH Seema Nayak, M.D. Director, Office of Clinical Research Resources National Institute of Allergy and Infectious Diseases, NIH Manizhe Payton, M.P.H. Director, Office of Clinical Site Oversight, DAIDS National Institute of Allergy and Infectious Diseases, NIH Laura Resnansky, B.S.N. Vice President, Global Head of Clinical Operations - Immunology, Infectious Diseases, Ophthalmology and Neuroscience Genentech Christine Sizemore, Ph.D. Director, Division of International Relations Fogarty International Center, NIH Badhri Srinivasan, A.B.D., M.S. Head, Global Development Operations Novartis Peter Stein, M.D. Director of Office of New Drugs, Center for Drug Evaluation and Research U.S. Food and Drug Administration Therese Takas Director, Clinical Operations AstraZeneca